340 related articles for article (PubMed ID: 25787336)
1. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
[TBL] [Abstract][Full Text] [Related]
2. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword.
Shuhendler AJ; Prasad P; Leung M; Rauth AM; Dacosta RS; Wu XY
Adv Healthc Mater; 2012 Sep; 1(5):600-8. PubMed ID: 23184795
[TBL] [Abstract][Full Text] [Related]
3. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an Integrin α
Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumors with cyclic RGD-conjugated lipid nanoparticles loaded with an IR780 NIR dye: In vitro and in vivo evaluation.
Choi J; Rustique E; Henry M; Guidetti M; Josserand V; Sancey L; Boutet J; Coll JL
Int J Pharm; 2017 Nov; 532(2):677-685. PubMed ID: 28279737
[TBL] [Abstract][Full Text] [Related]
6. α
Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
[TBL] [Abstract][Full Text] [Related]
7. RGD binding to integrin alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures.
Georgoulis A; Havaki S; Drosos Y; Goutas N; Vlachodimitropoulos D; Aleporou-Marinou V; Kittas C; Marinos E; Kouloukoussa M
Ultrastruct Pathol; 2012 Dec; 36(6):387-99. PubMed ID: 23181508
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
Zhang X; Chen X
Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent.
Anderson CR; Hu X; Zhang H; Tlaxca J; Declèves AE; Houghtaling R; Sharma K; Lawrence M; Ferrara KW; Rychak JJ
Invest Radiol; 2011 Apr; 46(4):215-24. PubMed ID: 21343825
[TBL] [Abstract][Full Text] [Related]
10. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
11. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
Rangger C; Helbok A; von Guggenberg E; Sosabowski J; Radolf T; Prassl R; Andreae F; Thurner GC; Haubner R; Decristoforo C
Int J Nanomedicine; 2012; 7():5889-900. PubMed ID: 23226020
[TBL] [Abstract][Full Text] [Related]
12. α
Qiu J; Cai G; Liu X; Ma D
Biomed Pharmacother; 2017 Dec; 96():1418-1426. PubMed ID: 29079344
[TBL] [Abstract][Full Text] [Related]
13. Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.
Xiong Z; Cheng Z; Zhang X; Patel M; Wu JC; Gambhir SS; Chen X
J Nucl Med; 2006 Jan; 47(1):130-9. PubMed ID: 16391197
[TBL] [Abstract][Full Text] [Related]
14. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells.
Wang Y; Wang X; Zhang Y; Yang S; Wang J; Zhang X; Zhang Q
J Drug Target; 2009 Jul; 17(6):459-67. PubMed ID: 19527117
[TBL] [Abstract][Full Text] [Related]
15. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125.
Kim YH; Jeon J; Hong SH; Rhim WK; Lee YS; Youn H; Chung JK; Lee MC; Lee DS; Kang KW; Nam JM
Small; 2011 Jul; 7(14):2052-60. PubMed ID: 21688390
[TBL] [Abstract][Full Text] [Related]
17. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
Shi S; Zhou M; Li X; Hu M; Li C; Li M; Sheng F; Li Z; Wu G; Luo M; Cui H; Li Z; Fu R; Xiang M; Xu J; Zhang Q; Lu L
J Control Release; 2016 Aug; 235():1-13. PubMed ID: 27235150
[TBL] [Abstract][Full Text] [Related]
18. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
19. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
20. Pigment epithelium-derived factor gene loaded in cRGD-PEG-PEI suppresses colorectal cancer growth by targeting endothelial cells.
Li L; Yang J; Wang WW; Yao YC; Fang SH; Dai ZY; Hong HH; Yang X; Shuai XT; Gao GQ
Int J Pharm; 2012 Nov; 438(1-2):1-10. PubMed ID: 22974524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
